We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Orforglipron (oral non-peptide GLP-1 receptor agonist)
An ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Prescription medication — not a dietary supplement
Orforglipron is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Orforglipron doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 559 participants.
Based on 51 studies · 11 meta-analyses · 18 RCTs · 2,067 total participants
Confidence
High confidenceBy outcome
Phase-3 RCTs show strong, consistent glycemic and weight benefit, but US approval (Foundayo, 1 April 2026) is recent, an EMA list dated 5 October 2026 places it under evaluation, and it has very common GI side effects and no long-term outcome data.
18 randomised trials
89% were about Orforglipron in an audit of 18 of them
Every randomised or controlled trial of Orforglipron indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
21 trials ongoing or recruiting · 32 completed on ClinicalTrials.gov
27 of the completed trials have posted results
Registered trials show research momentum for Orforglipron, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Orforglipron (development code LY3502970) is an oral, NON-PEPTIDE small-molecule GLP-1 receptor agonist developed by Eli Lilly for type 2 diabetes and obesity.
Unlike semaglutide or liraglutide — which are peptides that must be injected (or, for oral semaglutide, co-formulated with an absorption enhancer and dosed on an empty stomach) — orforglipron is a true small molecule resistant to enzymatic degradation, so it can be taken as a simple once-daily tablet with no food or water restrictions.
That pill-not-injection convenience, plus the absence of cold-chain logistics, is the entire reason the drug matters: it could make GLP-1 therapy far more scalable.
It is usually discussed alongside the peptide GLP-1 agents, but it is mechanistically a small molecule (closer in that respect to MK-677, an oral non-peptide growth-hormone secretagogue, than to the injectable peptides).
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression/satiety) and gut (slowed gastric emptying) — the same downstream cascade as the injectable GLP-1 agonists.
The evidence as of mid-2026 is genuinely encouraging but still maturing.
Two 2023 phase-2 dose-response RCTs established the signal: in type 2 diabetes (Frias et al., Lancet 2023; n=383) orforglipron cut HbA1c up to ~2.1% (placebo-adjusted ~1.7%) and bodyweight up to ~10 kg, beating both placebo and injectable dulaglutide; in obesity without diabetes (Wharton et al., NEJM 2023; n=272) it produced ~9-15% weight loss by week 36 vs ~2% on placebo.
The phase-3 program has begun reporting: ACHIEVE-1 (NEJM 2025; n=559) showed HbA1c reductions to ~6.5-6.7% with up to ~7.6% weight loss in early type 2 diabetes; ATTAIN-1 (NEJM 2025; n=3127) showed ~11.2% mean weight loss at 72 weeks at the 36 mg dose in obesity without diabetes; ATTAIN-2 (Lancet 2026; n=1613) showed ~9.6% weight loss at 72 weeks in obesity WITH type 2 diabetes (a smaller effect, as expected when diabetes is present); ACHIEVE-2 (Lancet 2026) showed superiority to dapagliflozin on HbA1c; ACHIEVE-3 (Lancet 2026; n=1698) was the first head-to-head against oral semaglutide and showed orforglipron 12/36 mg non-inferior and statistically superior on HbA1c; ACHIEVE-5 (JAMA 2026) showed added benefit on top of insulin glargine; and ATTAIN-MAINTAIN (Nat Med 2026) showed it preserves weight loss after switching off injectable therapy.
Regulatory status: In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026.
An EMA list dated 5 October 2026 places orforglipron under evaluation.
The honest counterweight: gastrointestinal adverse events (nausea, vomiting, diarrhea) are very common and dose-dependent, requiring slow titration, and treatment discontinuation has run higher than placebo and, in at least one indirect comparison, higher than oral semaglutide; a network meta-analysis found dose-dependent GI events and pancreatic-enzyme elevations (without clinical pancreatitis) over 26 weeks; the US Foundayo label carries a boxed warning about thyroid C-cell tumours and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2, and the human relevance of the preclinical concern is uncertain; and long-term cardiovascular, safety, and durability data are not yet in.
It must never be obtained from grey-market or research-chemical channels. US approval covers Foundayo dispensed on prescription, not material sold online as orforglipron. Products from unverified sources may have unreliable identity, strength or quality.
A small-molecule (non-peptide) agonist of the GLP-1 receptor, resistant to enzymatic degradation so it can be dosed orally — the single upstream target that drives all downstream metabolic effects, the same receptor the injectable GLP-1 peptides hit.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk (no severe hypoglycemia in the trials).
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the primary driver of the weight loss seen across the phase-2 and ATTAIN phase-3 trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the dose-dependent nausea seen during titration.
How Orforglipron works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated. The US Foundayo label carries a boxed warning about thyroid C-cell tumours and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. Human relevance of the preclinical concern is uncertain.
Use caution under specialist guidance, consistent with the GLP-1 class.
For US FOUNDAYO (orforglipron), the prescribing information says to discontinue treatment when pregnancy is recognised and contact the prescriber. The available pregnancy evidence does not establish safety.
Not appropriate. US approval covers Foundayo dispensed on prescription, not material sold online as orforglipron. Products from unverified sources may have unreliable identity, strength or quality.
The US FOUNDAYO prescribing information does not recommend use while nursing. Human milk, infant-effect and milk-production data are lacking. Discuss treatment with the prescriber; do not stop breastfeeding solely because of an app message.
Combining a GLP-1 agonist with insulin or sulfonylureas raises hypoglycemia risk; in ACHIEVE-5 it was added to titrated insulin glargine under trial supervision with insulin adjustment. Orforglipron alone showed no severe hypoglycemia.
Foundayo slows stomach emptying and may affect oral medicines. Ask the prescriber or pharmacist to review them. The US label advises people using oral hormonal contraception to use a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase.
Do not combine with another GLP-1 agonist (semaglutide, liraglutide, dulaglutide, tirzepatide) — additive GI risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Dose-dependent enzyme rises were seen without clinical pancreatitis in a network meta-analysis; clinical significance unclear
Tip: No increased pancreatitis risk detected in the 26-week meta-analysis, but it remains a GLP-1-class caution; seek urgent care for severe persistent abdominal pain
Orforglipron has an evidence score of 5.5/10 — moderate evidence based on 51 indexed studies, including 1 meta-analysis. An ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement. Representative study: PMID 42116665.
Dosing for Orforglipron: Use only as prescribed for the exact authorised formulation and indication, following its label and the treating clinician’s plan. No self-directed dose is recommended here.
Timing is flexible for Orforglipron — consistent daily use matters more than the time of day. Unlike oral semaglutide, orforglipron is a small molecule taken once daily with no food or water restrictions — a key practical advantage.
No consumer dose of Orforglipron is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis (class concern), treatment discontinuation due to GI events, nausea. How often they occur is not established for all of them. Use caution if any of these apply to you: Use only as a prescribed, authorised product under clinical care, or within an authorised clinical trial. Do not self-source orforglipron.; Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The US Foundayo label carries a boxed warning about thyroid C-cell tumours and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. Human relevance of the preclinical concern is uncertain.; History of pancreatitis (caution, consistent with the GLP-1 class).
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Mazdutide
Too few graded studiesAn investigational once-weekly injectable GLP-1 and glucagon receptor dual agonist (an oxyntomodulin analogue, IBI362/LY3305677) developed mainly in China by Innovent and Eli Lilly for obesity and type 2 diabetes. Honest appraisal: real phase-2 and phase-3 randomized trials show clinically meaningful weight loss (~12-17% at higher doses) and HbA1c reduction, but the evidence is almost entirely single-region (Chinese) and recent. It was approved in China in 2025 — it is NOT FDA-approved and is not available or approved in the West. It is a prescription drug, not a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 51 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research